Bexsero (Meningococcal Group B Vaccine) is a vaccine indicated for activeimmunizationto prevent invasive disease caused by Neisseria meningitides serogroup B. Bexsero is approved for use in individuals 10 through 25 years of age. What Are Side Effects of Bexsero? Common side effects of Bexsero in...
Meningococcal Group B Vaccine MenB GSK Rx Only For Use from 10 through 25 Years of Age 10 Disposable Single-Dose Prefilled TIP-LOK Syringes each containing one 0.5-mL dose TIP-LOK syringes to be used with Luer Lock compatible needles NEEDLES NOT INCLUDED BEXSERO Made in Italy ©...
Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered 90471: Immunization administration (includes percutaneous, intradermal, subcutaneous, or...
We aimed to assess the post-licensure safety profile of MenB-4C by examining reports received in the Vaccine Adverse Event Reporting System (VAERS). VAERS is a national passive surveillance system for adverse events (AEs) following immunization that uses the Medical Dictionary for Regulatory ...
Serogroup B is the only major disease-associated capsular group of Neisseria meningitidis for which no protein-polysaccharide conjugate vaccine is available. This has led to the development of multi-component protein-based vaccines that target serogroup B invasive meningococcal disease (IMD), including ...